H.C. Wainwright raised the firm’s price target on ArriVent Biopharma to $36 from $30 and keeps a Buy rating on the shares after the company presented initial clinical results from the randomized, Phase 1b FURTHER trial for firmonertinib in non-small cell lung cancer patients with EGFR PACC mutation. The results appear to reinforce firmonertinib’s potential in NSCLC patients harboring EGFR PACC mutations, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent announces PoC global Phase 1b interim data for firmonertinib
- Corbus Pharmaceuticals appoints Kung to board of directors
- ArriVent Biopharma price target raised to $30 from $25 at H.C. Wainwright
- ArriVent Biopharma reports Q2 EPS (65c), consensus (64c)
- ArriVent BioPharma Reports Second Quarter 2024 Financial Results